{"result": "{\n    \"title\": \"PLACEBO in Clinical Trials\",\n    \"summary\": \"The community centers around the use of PLACEBO as a control treatment in various clinical studies, including those evaluating treatments for septic shock, ARDS, and fever management in ICU patients. PLACEBO serves as a baseline for comparing the efficacy and safety of active treatments such as hydrocortisone, cisatracurium besylate, and acetaminophen. The studies span multiple regions, including Australia, New Zealand, Europe, and North and South America, highlighting the global scale of these trials.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical role of PLACEBO in determining the efficacy and safety of treatments in life-threatening conditions.\",\n    \"findings\": [\n        {\n            \"summary\": \"PLACEBO's role in evaluating septic shock treatments\",\n            \"explanation\": \"PLACEBO was utilized as a control treatment in studies assessing the effects of hydrocortisone on patients with septic shock. This approach allowed researchers to compare outcomes between those receiving hydrocortisone and those receiving PLACEBO, thereby evaluating the treatment's efficacy in managing septic shock [Data: Relationships (92, 109, 15, 106, 108)].\"\n        },\n        {\n            \"summary\": \"PLACEBO in ARDS and ICU studies\",\n            \"explanation\": \"In studies involving ARDS patients, PLACEBO was used as a control to compare against cisatracurium besylate, providing a baseline for evaluating treatment effects. Additionally, PLACEBO was administered to ICU patients to assess its impact on fever management and other physiological effects, ensuring accurate attribution of results to the treatments under investigation [Data: Relationships (94, 98, 103, 95, 100)].\"\n        },\n        {\n            \"summary\": \"Global recruitment for PLACEBO trials\",\n            \"explanation\": \"The clinical trials involving PLACEBO had a global reach, with recruitment sites in Australia, New Zealand, Europe, North America, South America, and India. This widespread recruitment underscores the international collaboration and significance of these studies in understanding treatment effects across diverse populations [Data: Relationships (68, 80, 46, 53, 54, 89)].\"\n        },\n        {\n            \"summary\": \"PLACEBO's impact on primary and secondary outcomes\",\n            \"explanation\": \"The primary outcome measured in the studies was the number of ICU-free days to day 28, with PLACEBO serving as a control. Secondary outcomes were also assessed to evaluate additional effects of PLACEBO, providing comprehensive insights into its role in the trials [Data: Relationships (101, 102, 178)].\"\n        },\n        {\n            \"summary\": \"PLACEBO's involvement in the CORTICUS study\",\n            \"explanation\": \"In the CORTICUS study, PLACEBO was used as a control to compare against hydrocortisone treatment. This study was pivotal in understanding the effects of hydrocortisone in critically ill patients, with PLACEBO providing a necessary baseline for comparison [Data: Relationships (111, 109)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n24,PLACEBO,\"PLACEBO is a control treatment used in various clinical studies to evaluate the effects of different active treatments. It was administered to patients as a comparison against cisatracurium besylate in ARDS patients, hydrocortisone in cases of severe sepsis or septic shock, and acetaminophen in ICU patients. In the CORTICUS study, PLACEBO was used to compare against hydrocortisone treatment. Additionally, it served as a control in trials assessing the effects of DrotAA, where it showed no significant difference in mortality rates. The placebo treatment typically consisted of 0.9 percent saline, with or without 0.1 percent human serum albumin, and was administered to 190 patients in one of the studies. Overall, PLACEBO played a crucial role in these studies by providing a baseline to measure the efficacy and safety of the active treatments being tested.\",31\n174,PATIENT CHARACTERISTICS,Patient characteristics were analyzed to compare baseline similarities and differences between study groups,2\n177,PHYSIOLOGICAL EFFECTS,\"The physiological effects of acetaminophen and placebo on patients, including body temperature changes\",2\n178,PRIMARY OUTCOME,The primary outcome measured in the study was the number of ICU-free days to day 28,2\n398,PNEUMONIA,A condition that was slightly more frequent in patients who received placebo during the study,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n92,PLACEBO,SEPTIC SHOCK,\"In the study, Placebo was utilized as a control treatment to evaluate the effects of hydrocortisone on patients suffering from septic shock. This approach allowed researchers to compare the outcomes of those receiving hydrocortisone against those receiving the placebo, thereby assessing the efficacy of the treatment in managing septic shock.\",101\n98,PLACEBO,ICU,\"In the study, a placebo was administered to patients in the Intensive Care Unit (ICU) as a control measure. This was done to evaluate the effects of the treatment being studied by providing a baseline for comparison. The use of a placebo in the ICU setting was integral to the study's design, ensuring that the results could be accurately attributed to the treatment under investigation.\",77\n110,PLACEBO,TRIAL,The trial involved administering a placebo to one group of patients,71\n109,PLACEBO,HYDROCORTISONE,Hydrocortisone and placebo were the two treatments compared in the trial,52\n15,DROTAA,PLACEBO,\"DrotAA was compared to placebo in a study involving critically ill adults with septic shock, showing no significant difference in mortality\",52\n103,PLACEBO,ACETAMINOPHEN,Acetaminophen and placebo were compared in a study to evaluate their effects on ICU patients with fever,44\n68,AUSTRALIA,PLACEBO,Australia was a recruitment site for patients receiving placebo in the clinical trial,44\n111,PLACEBO,CORTICUS STUDY,A placebo was used as a control in the CORTICUS study,43\n97,PLACEBO,SAS INSTITUTE,SAS Institute's software was used to analyze the effects of placebo in the study,42\n31,APACHE II,PLACEBO,APACHE II scores were used to assess the severity of illness in patients receiving placebo,42\n80,NEW ZEALAND,PLACEBO,New Zealand was a recruitment site for patients receiving placebo in the clinical trial,42\n105,PLACEBO,STUDY GROUP,The study group included patients assigned to receive placebo,40\n46,EUROPE,PLACEBO,Europe was a major recruitment site for patients receiving placebo in the clinical trial,40\n106,PLACEBO,SEVERE SEPSIS OR SEPTIC SHOCK STUDY,Placebo was used as a control treatment in the study,38\n108,PLACEBO,DELERIUM,Placebo was used as a control to compare the effects of hydrocortisone on delirium,35\n53,NORTH AMERICA,PLACEBO,North America was a recruitment site for patients receiving placebo in the clinical trial,35\n54,SOUTH AMERICA,PLACEBO,South America was a recruitment site for patients receiving placebo in the clinical trial,35\n94,PLACEBO,ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS),The placebo was used as a control in the study of ARDS patients to compare against the effects of cisatracurium besylate,34\n66,MARCH 2008,PLACEBO,Patient enrollment for the placebo group began in March 2008,34\n67,AUGUST 2011,PLACEBO,Patient enrollment for the placebo group ended in August 2011,34\n89,INDIA,PLACEBO,India was a recruitment site for patients receiving placebo in the clinical trial,34\n99,PLACEBO,PATIENT CHARACTERISTICS,Patient characteristics were analyzed to compare those receiving placebo,33\n100,PLACEBO,PHYSIOLOGICAL EFFECTS,\"The physiological effects of placebo were studied, including its impact on body temperature\",33\n91,PLACEBO,\"MAY 12, 2010\",\"The sample size for the placebo group was increased on May 12, 2010\",33\n93,PLACEBO,CISATRACURIUM BESYLATE,Cisatracurium besylate and placebo were compared in a study to evaluate their effects on ARDS patients,33\n95,PLACEBO,FEVER,Placebo was used as a control treatment in the study on fever management in ICU patients,33\n96,PLACEBO,INFECTION,Placebo was used as a control in the study on ICU patients with probable infection,33\n101,PLACEBO,PRIMARY OUTCOME,The primary outcome measured the effect of placebo on ICU-free days,33\n102,PLACEBO,SECONDARY OUTCOMES,Secondary outcomes were measured to assess additional effects of placebo,33\n104,PLACEBO,BINATIONAL TRIAL,The binational trial used placebo as a control to compare against acetaminophen,33\n107,PLACEBO,PNEUMONIA,Pneumonia was slightly more frequent in patients who received placebo,32\n581,ACETAMINOPHEN,PATIENT CHARACTERISTICS,Patient characteristics were analyzed to compare those receiving acetaminophen,15\n582,ACETAMINOPHEN,PHYSIOLOGICAL EFFECTS,\"The physiological effects of acetaminophen were studied, including its impact on body temperature\",15\n583,ACETAMINOPHEN,PRIMARY OUTCOME,The primary outcome measured the effect of acetaminophen on ICU-free days,15\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}